Drug Trial Radar · NCT05055908
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
Last checked: Nov 20, 2026Latest source record: Aug 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12,000
Planned (sponsor's estimate)
Start
Oct 1, 2021
Primary completion
Jul 1, 2025
Study completion Sep 14, 2027
Sponsor
- Lead sponsor
- Hunan Province Tumor HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to find some biomarkers to predict the the adverse events of Immune Checkpoint Inhibitors monotherapy or plus platinum based chemotherapy in lung cancer.
Conditions
- Lung Cancer
Interventions
Pemetrexed plus PembrolizumabDrug
Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc. Pemetrexed, 500mg/m2, ivgtt, every 21 days
PembrolizumabDrug
Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc.
PemetrexedDrug
Pemetrexed, 500mg/m2, ivgtt, every 21 days etc.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Correlation between Adverse events (AEs) and gene profileTime frame: Time from first subject dose to study completion, or up to 36 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.